Antimicrobial drug discovery : emerging strategies /

• Format: eBook
• Language: English
• Published: Wallingford, Oxfordshire, UK : CABI, 2012.
• Series: Advances in molecular and cellular microbiology ; 22.
• Subjects: Anti-infective agents > Development.; Drug development.; Drug resistance.; Anti-Infective Agents > pharmacology.; Drug Design.; Disease Models, Animal.; High-Throughput Screening Assays > methods.; Photosensitizing Agents > pharmacology.; Prion, Viral, Bacterial and Fungal Pathogens of Humans, (New March 2000); Animal Models of Human Diseases, (New March 2000); Animal and in vitro Models for Pharmaceuticals, (New March 2000); Non-drug Therapy and Prophylaxis of Humans, (New March 2000); Biosensors and Biological Nanotechnology, (New June 2002); Biochemistry and Physiology of Microorganisms, (New March 2000); Bacteria.; Fungi.; Acetyl-CoA carboxylase.; Animal models.; Antibacterial agents.; Antifungal agents.; Bacterial diseases.; Biofilms.; Disease models.; Drug susceptibility.; Drug targets.; Human diseases.; Laboratory animals.; Lipopolysaccharides.; Mycoses.; Peptide antibiotics.; Phototherapy.; Resistance mechanisms.; Structure activity relationships.; Electronic books.
• Online Access: View fulltext via EzAccess
• Physical Description: 1 online resource (x, 357 pages) : illustrations, charts.; Also available in print format.
• Bibliography: Includes bibliographical references and index.
• Access: Access limited to subscribing institution.

This book, inclusive of 22 chapters, describes novel approaches currently used for antimicrobial drug discovery, focusing on agents for use against bacterial and fungal pathogens. Specific chapters discuss: (1) concepts relevant to drug resistance; (2) microbial mechanisms related to efflux pumps and studies on their potential inhibitors; (3) impact of multidrug tolerance of biofilms and persister cells; (4) bacterial quorum-sensing inhibition; (5) inhibition of the bacterial filamentous temperature-sensitive mutant Z (FtsZ); (6) antibacterial properties of lysostaphin; (7) strategies to identify modified ribosomally synthesized antimicrobials; (8) quantitative structure-activity relationship studies of novel antimicrobial peptides; (9) bacterial acetyl-CoA carboxylase and lipopolysacharide as drug targets for antibiotic development; (10) pathosystematic systems biology for the rational design of novel antifungal compounds; (11) specific animal models for novel antimicrobial discovery; and (12) new antimicrobial technology platforms such as antimicrobial photodynamic therapy and carbon nanotubes.